Dr. Lal Path Labs Q1FY24 consolidated PAT up at Rs. 82.6 Cr

Dr. Lal Path Labs Ltd. has reported total income of Rs. 555.4 crores during the period ended June 30, 2023

Ajanta Pharma's Q1 FY24 consolidated PAT up at Rs. 208.12 Cr

The company has reported total income of Rs. 1052.79 crores during the period ended June 30, 2023

Biocon Foundation releases 2nd edition of consensus guidelines for head & neck cancer

Marks the World Head & Neck Cancer Day at the OCTF Conference

GenWorks introduces mechanical hysteroscopic tissue removal system

Uses a simple mechanical approach for removing intrauterine tissues

Cipla reports jump in Q1FY24 consolidated PAT to Rs. 995.70 Cr

Cipla has reported total income of Rs. 6465.18 crores during the period ended June 30, 2023

InnoCare gets approval of clinical trial of Zurletrectinib for the treatment of pediatric patients in China

Zurletrectinib was developed to treat advanced or metastatic solid tumors harboring NTRK fusion genes

Akums gets approval for triple combination diabetes treatment

Syngene Q1 FY 2024 revenue up 26% to Rs. 832 crores, PAT up 26% to Rs.93 Cr

Acquisition of biologics manufacturing facility in Bangalore to complete by the end of the third quarter in FY 24

Jubilant Ingrevia consolidated Q1 FY2024 PAT up QoQ at Rs. 57.59 Cr

Jubilant Ingrevia has reported total income of Rs. 1083.52 crores during the period ended June 30, 2023

DGHS organizes National Webinar on National Organ and Tissue Transplant Organisation

Six engaging sessions focusing on Prevention of Kidney Diseases, Brain Stem Death Declaration, Deceased Donor Management, Prevention of Liver Diseases, Legal Aspects of Organ and Tissue Donation, Eye Donation and Corneal Transplant held as part of the Webinar

India brings traditional medicine at the forefront of India’s G20 presidency discourse: Amitabh Kant

Traditional medicine effectively highlighted in all health and engagement working groups meeting and Ministry of Ayush acknowledges these efforts

Lonza delivers 5.6% CER sales growth and 30% CORE EBITDA margin

Good momentum in commercial CDMO business

Merck receives positive European Union CHMP opinion for Gefapixant

The CHMP’s recommendation will now be reviewed by the European Commission for marketing authorization in the European Union

Boehringer Ingelheim receives FDA approval for NexGard Plus

The maker of ivermectin/pyrantel, the #1 vet-recommended and #1 dog-preferred real beef chew introduces the latest innovation in its portfolio

Lupin launches Luforbec 100/6 for adult asthma and COPD treatment in Germany

Luforbec® 100/6 pMDI aims to provide comprehensive support to patients and healthcare professionals

Glenmark Life Sciences reports robust 25% EBITDA growth in Q1FY24

The net profit in the June quarter was also lower than Rs 146.3 crore reported in the March quarter.

Tillotts Pharma and TVM Capital form Mage Biologics to develop oral antibody therapy for ulcerative colitis

Mage Biologics to develop a monoclonal antibody targeting ulcerative colitis

Kintor Pharma completes first patient enrollment in long-term safety phase III trial of KX-826

The Long-term Safety Trial was approved to be conducted by China National Medical Products Administration (NMPA) on 18 April 2023

M&A activity of pharma CMOs will continue despite challenging borrowing environment, says GlobalData

CMOs showed an increasing reluctance to take on debt in 2022

Wockhardt Hospitals, Mira Road launches training program for family physician

To equip them with the latest knowledge and skills to handle patients coming to them in a better way